Please login to the form below

Not currently logged in
Email:
Password:

Sandoz

This page shows the latest Sandoz news and features for those working in and with pharma, biotech and healthcare.

Generic Differentiation

Generic Differentiation

Branded generics, such as Sandoz, aim at the first market. A myriad of white-label manufacturers, mostly in emerging markets, aim for the second.

Latest news

  • NHS says Humira biosimilar deal will save £300m NHS says Humira biosimilar deal will save £300m

    end. Amgen’s copy Amgevita and Samsung and Biogen’s Imraldi both gained full EU approval last year, and have been joined since by Hyrimoz from Novartis’ Sandoz division, Boehringer ... NHS England says it has accepted bids from four companies –

  • Novartis buys cancer specialist Endocyte for $2.1bn Novartis buys cancer specialist Endocyte for $2.1bn

    the back of gains for new psoriasis drug Cosentyx (secukinumab) and Entresto (sacubitril/valsartan) for heart failure – up 37% to $750m and 113% to $271m, respectively – as well as Sandoz’ biosimilar

  • First Humira biosimilars reach EU market First Humira biosimilars reach EU market

    Copycat versions of the TNF inhibitor  from Amgen, Samsung Bioepis/Biogen, Mylan/Fujifilm Kyowa Kirin, and Novartis’ Sandoz unit are starting to become available in their first EU markets now that ... Among those launched on the day patent protection

  • Novartis sells off part of Sandoz portfolio Novartis sells off part of Sandoz portfolio

    The move, which will see Sandoz do away with its lower margin segments of US dermatology and generic oral solid portfolios, allows the firm to re-focus its business. ... In return Aurobindo is set to receive approximately 300 products, as well as

  • Daily Brief: Biosimilars ready to pounce on Humira, Hong Kong could rival Nasdaq, Kymab's OX40 candidate Daily Brief: Biosimilars ready to pounce on Humira, Hong Kong could rival Nasdaq, Kymab's OX40 candidate

    Meanwhile Sandoz (a Novartis division) announced on Friday that it too has now gained European approval for its biosimilar, to be known as Hyrimoz. ... Kavya Gopal, Head of Specialty at Sandoz UK said: “The approval of Hyrimoz has the potential to have

More from news
Approximately 15 fully matching, plus 161 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2018

    radioligands and CAR‐T for cancer. $2.1B. Sale. Aurobindo. NovartIs sold part of Sandoz’s US generics. ... Sandoz’s US business has retained its biosimilars, value‐added medicines and complex generics, including the ophthalmology products.

  • Innovation in merger control and the impact on the pharmaceutical sector Innovation in merger control and the impact on the pharmaceutical sector

    In Ciba-Geigy/Sandoz, the FTC was concerned that the merger could impair the development of gene therapy, a market that the FTC forecast to be worth US$45bn within 20 years

  • Building a bright future Building a bright future

    Mylan’s biosimilar of the multiple sclerosis injection therapy copaxane is not gliding to the promised land, and delays have given rivals Momenta and Novartis’ Sandoz a tilt at the

  • Deal Watch November 2016 Deal Watch November 2016

    In May this year Sandoz announced that a regulatory submission for its version of rituximab had been accepted by the EMA following multiple clinical trials in over 800 patients.

  • Deal Watch October 2016 Deal Watch October 2016

    Even without non-exclusive deals from one supplier, there is the additional competitive risk of new biosimilar entrants, such as Sandoz, etcetera.

More from intelligence
Approximately 0 fully matching, plus 20 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 18 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics